Publication:
Improving the estimation of the global burden of antimicrobial resistant infections

dc.contributor.authorDirek Limmathurotsakulen_US
dc.contributor.authorSusanna Dunachieen_US
dc.contributor.authorKeiji Fukudaen_US
dc.contributor.authorNicholas A. Feaseyen_US
dc.contributor.authorIruka N. Okekeen_US
dc.contributor.authorAlison H. Holmesen_US
dc.contributor.authorCatrin E. Mooreen_US
dc.contributor.authorChristiane Doleceken_US
dc.contributor.authorH. Rogier van Doornen_US
dc.contributor.authorNandini Shettyen_US
dc.contributor.authorAlan D. Lopezen_US
dc.contributor.authorSharon J. Peacocken_US
dc.contributor.otherPublic Health Englanden_US
dc.contributor.otherThe University of Hong Kong Li Ka Shing Faculty of Medicineen_US
dc.contributor.otherMalawi-Liverpool-Wellcome Trust Clinical Research Programmeen_US
dc.contributor.otherUniversity of Cambridgeen_US
dc.contributor.otherUniversity of Oxforden_US
dc.contributor.otherUniversity of Melbourneen_US
dc.contributor.otherImperial College Londonen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Ibadanen_US
dc.contributor.otherOxford University Clinical Research Uniten_US
dc.date.accessioned2020-01-27T09:24:46Z
dc.date.available2020-01-27T09:24:46Z
dc.date.issued2019-11-01en_US
dc.description.abstract© 2019 Elsevier Ltd Estimating the global burden of disease from infections caused by pathogens that have acquired antimicrobial resistance (AMR) is essential for resource allocation and to inform AMR action plans at national and global levels. However, the scarcity of robust and accepted methods to determine burden is widely acknowledged. In this Personal View, we discuss the underlying assumptions, characteristics, limitations, and comparability of the approaches used to quantify mortality from AMR bacterial infections. We show that the global burdens of AMR estimated in previous studies are not comparable because of their different methodological approaches, assumptions, and data used to generate the estimates. The analytical frameworks from previous studies are inadequate, and we conclude that a new approach to the estimation of deaths caused by AMR infection is needed. The innovation of a new approach will require the development of mechanisms to systematically collect a clinical dataset of substantial breadth and quality to support the accurate assessment of burden, combined with decision-making and resource allocation for interventions against AMR. We define key actions required and call for innovative thinking and solutions to address these problems.en_US
dc.identifier.citationThe Lancet Infectious Diseases. Vol.19, No.11 (2019), e392-e398en_US
dc.identifier.doi10.1016/S1473-3099(19)30276-2en_US
dc.identifier.issn14744457en_US
dc.identifier.issn14733099en_US
dc.identifier.other2-s2.0-85073606951en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/51344
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073606951&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleImproving the estimation of the global burden of antimicrobial resistant infectionsen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073606951&origin=inwarden_US

Files

Collections